REPROCELL
Urmila Sreenivasan is a Research and Development Scientist specializing in Stem Cell Services at REPROCELL since November 2021. Expertise includes cardiomyocyte differentiation, neuronal differentiation, fibroblast derivation, reprogramming fibroblasts to induced pluripotent stem cells (iPSCs), and expanding iPSCs for clinical and research applications with quality control measures. Prior roles at the University of Maryland, Baltimore, from October 2005 to November 2021, included Research Lab Supervisor and Research Specialist, involving extensive experience in stem cell and tissue culture, various biochemical assays, RNA and DNA extraction, and molecular biology techniques. Urmila Sreenivasan holds an MS in Medical and Research Technology from the University of Maryland and an M.Phil. in Life Science along with a Master's in Life Science with a specialization in Environmental Science from the University of Kerala.
This person is not in any offices
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.